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Utilization of alpha-.ketoisocaproate for protein synthesis in uremic
rats. We have recently shown that the nutritional efficiency, R, of
alpha—ketoisocaproate (KIC) as a substitute for leucine, defined as the
ratio of the dose of leucine to the dose of KIC (on a leucine—free diet)
for equal growth, can be evaluated isotopically: '4C-KIC and 3H-leucine
are administered p.o.; six hours later, '4C/3H in the leucine of whole
body protein, divided by '4CPH in the injectate, gives a value indistin-
guishable from R assessed in the same animals by growth experiments.
To see how chronic uremia affects R, 11/12 nephrectomized rats and
sham—operated controls were fed a regular diet for 15 days and then
given these isotopes p.o. Six hours later, R, measured in whole body
protein, and in the protein of brain, heart, muscle, salivary gland, liver,
and the kidney remnant was significantly greater than in sham—operated
controls. The greatest difference (39%) was seen in liver protein and the
smallest difference (19%) in muscle. Thus chronic uremia increases the
efficiency, relative to leucine, with which KIC is utilized for protein
synthesis in all of these organs and in the body as a whole. Possible
explanations are discussed.
One approach to the nutritional therapy of chronic renal
failure, currently under study, is the provision of one of several
mixtures of the three branched—chain ketoacids (BCKA) (ana-
logues of valine, leucine, and isoleucine), N-free analogues of
other essential amino acids, and various amino acids as such,
given as a supplement to a very low—protein diet. This regimen
has been shown to reduce urea appearance and other biochem-
ical signs of uremic toxicity more than can be explained by the
substitution of N-free analogues for N-containing amino acids
[1]. This effect may be attributable to an inhibitory effect of
BCKA, and aipha—ketoisocaproate (KIC) in particular, on
protein breakdown, demonstrable in isolated tissues [2—4],
fasting man [5, 61, and post-operative patients [7], and not
shared by leucine itself. Thus KIC exerts two distinct effects on
N balance: 1. if transaminated, it provides a source of leucine in
diets otherwise inadequate in leucine, and 2. as such, it inhibits
proteolysis. Knowledge of the fraction of administered KIC
transaminated in uremia would therefore be of interest.
In the first report of the treatment of chronic renal failure with
such a dietary regimen, the mixture employed contained three
times as much BCKA as other essential amino acids or ana-
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logues [1]. The reason for this was that studies of isolated
perfused rat liver had shown that substantial fractions of each
BCKA were oxidized rather than transaminated [8].
Chawla, Stackhouse and Wadsworth [9] compared the
growth of rats fed aipha—ketoisocaproate (KIC) in place of
leucine, and reported that four to five times as much KIC was
required to achieve equal growth. They defined nutritional
efficiency of KIC as the ratio of the dose of leucine to the dose
of KIC for equal growth. Their results indicate that nutritional
efficiency of KIC in the rat is 0.20 to 0.27. Recently we have
shown that nutritional efficiency of KIC can be measured less
laboriously by an isotopic method: '4C-labelled KIC and 3H-
labelled leucine are administered orally. Six hours later, 14C/3H
is measured in the leucine of whole body protein, and divided
by '4C/3H in the injected mixture. The resulting ratio, R, was
shown to be indistinguishable from nutritional efficiency of KIC
assessed in the same animals by study of comparative growth
rates [10]. Furthermore, the same R value was seen in rats
continuously infused for six hours as in rats sampled six hours
after a single injection [11].
In the present work, this technique has been applied to
subtotally nephrectomized rats in order to assess the effect of
chronic uremia on nutritional efficiency of KIC.
Methods
Animals
Fourteen Sprague—Dawley rats weighing 285 to 310 g were
randomly assigned to two groups. They were anesthesized with
sodium pentobarbital, 50 mg/kg body weight intraperitoneally
on day 0. After a midabdominal incision, rats in Group I were
11/12 nephrectomized by ligating two or more extrarenal
branches of the left renal artery and removing the right kidneys.
In Group II, rats were sham—operated by decapsulation of both
kidneys. They were kept in individual cages. Group I rats were
fed ad lib with a regular diet. Group II rats were pair—fed with
the same diet. One rat of Group I died on the second postop-
erative day (day 2) because of wound dehiscence and intraperi-
toneal bleeding, and another rat died on day 4. These two rats
and their matched control pairs were excluded from the study.
Body weight and food intake were recorded daily. Two days
before isotope administration (day 14), rats were placed in
individual metabolic cages for 24-hour urine collection. Water
and food were provided as before.
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Fig. 1. Feed intake in 11/12 nephrectomized rats (open circles) com-
pared with pair—fed sham—operated controls (closed circles). A signif-
icant difference is seen only on day 12.
Preparation of isotope mixture
250 Ci of 2-keto (l-'4C) isocaproic acid, sodium salt (54
mCilmmol, Amersham, Arlington Heights, Illinois, USA), was
dissolved in 12.5 ml of normal saline containing 100 mg of the
sodium salt of 2-ketoisocaproic acid (KIC). 250 sCi of L-(4,5-
3H)-leucine (55 Ci/mmol, ICN Pharmaceuticals, Irvine, Califor-
nia, USA), was added to 12.5 ml of saline containing 100 mg of
L-leucine. These two isotope solutions were mixed together in
an ice bath, then transferred to separate empty glass vials, 10 ml
each, and quickly frozen in dry ice—acetone. The vials were
kept at —20°C until use.
Isotope administration
In the evening of day 15, food was withdrawn but water was
still provided ad lib. On day 16 (12 hours later), 5 ml of the
isotope mixture solution (containing 10 Ci of '4C-KIC and 10
Ci of 3H-leucine) was injected into the oropharynx via a large
bore needle fitted with a bulb, under light ether anesthesia.
They were kept in individual cages without food or water and
killed six hours after isotope injection by intracardiac blood
aspiration. The heart, part of the liver, left kidney, both
submandibular salivary glands, a portion of muscle of the left
thigh, and both cerebral hemispheres were removed and stored
at —20°C. The remaining carcasses were wrapped in aluminum
foil and kept at —20°C.
Specimen processing
All specimens were analyzed within two weeks. The car-
casses were autoclaved at 120°C for 30 minutes and blended
with 150 ml of water until a homogeneous slurry was obtained.
Aliquots of 1.5 to 2.0 ml were transferred to a glass homogeni-
zation tube with 2 ml of water and further homogenized.
Visceral organs were pulverized in a pre-cooled mortar by using
liquid nitrogen, then homogenized similarly.
Tissue proteins were separated and counted as described
previously [10].
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Fig. 2. Growth of 11/12 nephrectomized rats (open circles) compared
with pair—fed sham-operated controls (closed circles). No significant
difference are seen. Both groups lost weight for one week, then grew at
a slow rate.
Calculation of R and statistical analysis
R '4C dpm I 3H dpm in protein
'4C dpm I 3H dpm in injectate
Statistical analyses were made by paired t-test and analysis of
variance followed by Duncan's multiple—range test [12].
Results
Weight change and food intake of the two groups, as shown
in Figures 1 and 2, were similar. The comparison of food intakes
was made by comparing the intakes each day in Group I rats
with intakes the following day by the matched pair—fed Group II
rats. To minimize the effect of body weight difference, we
expressed these values per 100 g body weight. During the 15
days of observation, a similar pattern of food intake in both
groups was observed except the average food intake on day 11
in Group 1 (7,54 0.68 gIlOO g body weight), which was
significantly higher than that on day 12 of Group 11(7.25 0.62
gIlOO g body weight, P <0.05).
At the end of this 15 day period, in Group I rats, serum urea
nitrogen and creatinine were higher than those in Group TI rats
(Table 1). Creatinine and urea clearances were also lower in
Group I than in Group 11. Serum albumin and transferrin did not
significantly differ between the two groups. However, these
values tended to be lower in the nephrectomized rats.
R ratios of whole body protein and tissue proteins are shown
in Table 2. R was higher in Group 1 rats than in Group 11, in
whole body protein and in each tissue protein examined,
indicating that KIC is generally more effectively utilized for
protein synthesis (relative to leucine) in the uremic state than in
controls.
The "within" group R of each organ was compared. In Group
1 rats, Rbi8 was not different from Rheart but was significantly
higher than R of other organs (Rmuscie, P <0.05; Rsaiivary gand
<0.05; RkdflY, P < 0.01 Rwhoie body, P < 0.05; Riiver, P < 0.01).
had the lowest value. However, differences among other
R values in this group were insignificant. A similar observation
was made in Group 11 rats. Rbrain was significantly higher than
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Table 1. Body weight and blood chemistry of rats, means SEM
Uremic rats Control rats P
Body weight, day 0 g 291.8 2.6 290.0 1.3 NS
Body weight, day 15 g 268.7 11.0 278.2 10.2 NS
Rate of change of weight
g/day —1.54 0.83 —0.79 0.72 NS
Serum albumin gIdi 1.4 0.2 2.1 0.2 NS
Serum transferrin mg/dl 83.0 7.8 103.8 6.6 NS
Serum urea N mgI dl 46.2 7.6 11.0 1.2 <0.025
Serum creatinine mg/dl 1.30 0.14 0.40 0.03 <0.005
Creatinine clearance mi/mm 0.57 0.12 1.97 0.23 <0.025
Urea clearance mI/mm 0.36 0.07 1.17 0.18 <0.05
Rkidney. Rwhole body Riiver, and other R's within Group II did not
differ significantly.
The effect of chronic uremia on KIC utilization was greatest
in liver, where R was 39% higher than controls, and least in
muscle, where R was only 19% greater.
The whole body R values indicate that the dose of KIC
required to achieve equal growth rates in the uremic animal
would be 64% greater than the dose of leucine, in contrast to
sham—operated pair—fed animals, in which a dose 104% greater
would be required.
Discussion
These results show that KIC is incorporated into protein
more extensively in rats with chronic renal failure than in
sham—operated controls. From our previous work [10] we can
infer that less KIC would be required as a substitute for leucine,
in uremic animals than in control animals, to achieve the same
growth rate as in rats fed leucine.
The efficiency with which branched—chain ketoacids are
converted to the corresponding branched—chain amino acids in
growing rats has usually been found to be under 100%. Meister
and White [13] found that rats grew as well on diets containing
KIC or KIV as on diets containing leucine or valine, respec-
tively, but rates of growth were only 2 g per day (or less), for
unknown reasons. Wood and Cooley [14] observed slower
growth in BCKA-substituted diets. Chow and Walser [15]
observed reduced growth of rats fed KIV in place of valine, or
all three BCKA in place of BCAA. Chawla and Rudman [16]
found the nutritional efficiency of KIV relative to valine in the
rat to be 37% to 80%. As noted earlier, Chawla, Stackhouse and
Wadsworth [9] reported nutritional efficiency of KIC relative to
leucine to be 20% to 27%. However, Chow and Walser [17]
reported that substitution of KIV for valine in rats fed a
nitrogen—restricted diet did not impair growth, implying 100%
utilization of KIV on this diet. Protein restriction substantially
increases the nutritional efficiency of KIC relative to leucine, as
we have shown recently using this isotopic technique [18].
In normal dogs, Abumrad et al [19] found that 36% of an oral
dose of KIC was transaminated to leucine by the liver, and 83%
of the KIC reaching the kidney was transaminated.
In man, Rudman [20] observed that KIV at a dose equal to
the minimum daily requirement of valine reduced by approxi-
mately half the negative N balance of a valine—free diet in three
subjects. Gallina, Dominguez, and Hoschoian [21] found that
neither 1.17 glday nor 2.25 glday of the sodium salt of KIV was
adequate to restore N balance in a woman on a valine—free diet,
Table 2. R values of protein of various organs and whole body in
uremic and control rats, means SEM
Uremic rats Control rats P
Heart 0.68 0.04 0.54 0.06 <0.01
Liver 0.59 0.06 0.42 0.05 <0.01
Kidney 0.61 0.05 0.46 0.05 <0.001
Salivary gland 0.63 0.04 0.50 0.05 <0.001
Brain 0.81 0.04 0.64 0.03 <0.001
Muscle 0.64 0.05 0.54 0.05 <0.025
Whole body 0.61 0.05 0.49 0.04 <0.001
but 3.52 g/day was adequate. Halliday et al [221 estimated the
conversion of KIV to valine in normal as well as uremic
subjects to be 25 to 50%, by measuring '3C02 in expired air.
Epstein et al [23] showed that oxidation of orally—administered
labelled KIV was reduced on a protein—restricted diet in normal
subjects. Mitch and Walser [24, 25] found that mixtures con-
taining 3.8 g/day of KIC and 2.7 glday of KIV sufficed to
maintain N balance in uremic patients on diets devoid of valine;
since these doses are approximately twice the daily require-
ments of these amino acids, nutritional efficiency of KIC and
KIV must be at least 50%.
Although several reports have documented the extent of
oxidation or utilization of BCKA in uremic patients [22, 24—26]
there are few comparisons of normal with uremic subjects. Arai
et al [27] recently compared the change in plasma valine
following KIV loads in normal vs. uremic subjects: the incre-
ment appeared to be greater in the uremic subjects, but no
statistical comparison was made. Halliday et al [22] could
detect no difference in utilization of KIV between uremic and
normal subjects in their small series.
The explanation of the difference between uremic and control
rats in KIC utilization is not apparent. It cannot be the level of
protein intake [18], because the animals were pair—fed the same
diet, nor can it be rate of change of weight, which was almost
indistinguishable in the two groups (Fig. 2). All organs studied
exhibited this effect, although the magnitude of the difference
varied (liver > kidney > brain = salivary gland = heart >
muscle) (Table 2). Conceivably, the changes observed in organs
other than the liver may have been secondary to the change that
occurred in the liver. Thus, lessened oxidation of KIC by the
liver in uremic animals would permit more KIC to reach
peripheral organs where it can be transaminated to leucine.
Confirmation of this hypothesis would require a comparison of
the fates of these two isotopes administered intravenously in
uremic animals or patients.
It should be noted that these results have no bearing on the
protein—sparing effect of KIC, mentioned in the introduction,
nor on its possible value in the therapy of uremia.
The rate of oxidation of BCKA is dependent on many factors
that could be altered in uremia, including the redox state of
mitochondria [28], the level of acylcarnitines [28], alpha—adren-
ergic agonists [291, the level of free fatty acids [30, 31], the
concentration of BCKA [32], which are reduced in uremia [34,
35], tissue calcium [36], ATP levels [36, 37] and other factors.
Differences in the availability of amino acids for transamination
could also affect the rate of transamination. And finally, there
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could be changes in the efficiency of intestinal transport [38,
39]. As we have pointed out elsewhere [10], the technique
employed here measures the global effect of all such processes
on nutritional efficiency. Further study will be required to
elucidate the role of these factors in modifying the fate of
BCKA in uremia.
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